Announcement PDF ASX Announcement 12 July 2024 Microba Diagnostics Business Update to Bioshares Summit Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”) is pleased to announce that Chief Executive Officer, Dr Luke Reid will present at the 18th Bioshares Biotech Summit in Perth, Australia at 6.55pm AEST/ 4.55 AWST (Perth time) tomorrow. Founded on world-leading metagenomic microbiome analysis technology, Microba has been executing on a clear vision for routine use of clinical diagnostic microbiome testing, and novel effective therapeutics developed using this technology. In this presentation, CEO Luke Reid will present on the recent launch of Microba’s diagnostic products and next step in its journey as a medical diagnostics company at the forefront of the clinical application of microbiome testing. The subject of the Bioshares presentation is ‘Unlocking the diagnostic application of microbiome testing’. A copy of the Bioshares Biotech Summit presentation is attached below. This announcement has been authorised for release by the Board of Directors For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com View this announcement on our Investor Hub: https://ir.microba.com/link/VyEBbe . JOIN MICROBA’S INTERACTIVE INVESTOR HUB ir.microba.com/welcome interact with Microba’s announcements and updates by asking questions and comments which our team can respond to where possible. Microba Life Sciences Ltd ABN 82 617 096 652 Level 10, 324 Queen Street, Brisbane QLD 4000 Australia, 1300 974 621 Unlocking the diagnostic application of microbiome testing Bioshares Biotech Summit 2024 ASX: MAP 12 July 2024 Authorised for release by the Board of Directors Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its absolute discretion, but without being under any obligation to do so, update or supplement this Presentation. The information in this Presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible investment in Microba or that would be required in a prospectus or other disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act). Industry and market data – In this Presentation, Microba refers to certain market, industry, and statistical data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither Microba nor its representatives have independently verified any such data and no representation or warranty, express or implied, is made as to its fairness, accuracy, correctness, completeness or adequacy. Some data is also based on the good faith estimates of Microba, which are derived its reviews of internal sources as well as the independent sources described above. Not an offer - This Presentation is not a prospectus or other disclosure document under the Corporations Act and will not be lodged with the Australian Securities and Investments Commission. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this Presentation (including electronically) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice. Any non-compliance with these restrictions may contravene applicable securities laws. Not investment or medical advice - The information contained in this Presentation is not investment, financial product advice, medical advice or any medical recommendation or recommendation to acquire Shares. This Presentation has been prepared without taking into account your investment objectives, financial situation, medical or any other particular needs This Presentation does not and will not form any part of any contract for the acquisition of shares. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation. Before making an investment decision, you should consider whether it is a suitable investment for you in light of your own investment objectives, financial situation and particular needs and having regard to the merits or risks involved. Independent financial advice is recommended. Future performance - This Presentation contains forward looking statements. Forward-looking statements generally relate to current expectations, hopes, beliefs, intentions, strategies or productions about future events or Microba's future financial or operating performance. For example, statements regarding anticipated growth in the industry in which Microba operates and anticipated growth in demand for Microba's products and services, projections of Microba's future financial results and other metrics are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forwardlooking. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance and may involve known and unknown risks, uncertainties and other factors, many of which are outside the control of Microba. You are cautioned not to place undue reliance on any forward looking statement. Forward looking statements in this Presentation are based on assumptions and contingencies which are subject to change without notice. Actual results, performance or achievements may vary materially from any forward looking statements and the assumptions on which statements are based. The forward looking statements in this Presentation are based on information available to Microba as at the date of this Presentation and nothing in this Presentation should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Except as required by law or regulation, Microba undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. Financial data – All dollar values in Australian dollars (A$ or $) unless otherwise stated. Recipients should note that this Presentation contains historical and pro-forma financial information. Any financial information provided in this Presentation is for illustrative purposes only and is not represented as being indicative of Microba’s views on its future financial condition and/or performance. Trademarks – This Presentation may contain trademarks, trade names and copyrights of other companies, which are the property of their respective owners. Solely for convenience, some of the trademarks, trade names and copyrights referred to in this Presentation may be listed without the © or ® symbols, but Microba asserts, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, trade names and copyright. Disclaimer - Except for any statutory liability which cannot be excluded, Microba, its related bodies corporate and their respective officers, employees and advisers expressly disclaim all liability (including negligence) for any direct or indirect loss or damage which may be suffered by any person in relation to, and take no responsibility for, any information in this Presentation or any error or omission therefrom, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of this Presentation. 2 Microba is a medical diagnostic and clinical stage therapeutics company unlocking the human microbiome • Microba was founded in late 2017 on world-leading metagenomic microbial genomic and microbiome analysis technology • A clear vision for routine use of diagnostic metagenomic testing, and novel drugs developed using this technology • Foundations and initial revenue built through non-diagnostic testing services with over 50,000 tests sold to date • Microba’s Testing business invested to develop 2 diagnostic testing products: Gastrointestinal disorder test – Launched Feb 2023 Gastrointestinal pathogen test – Launched March 2024 • Microba’s Therapeutics business invested in 3 programs: Inflammatory Bowel Disease – Phase I complete Immuno-Oncology – Preclinical lead candidate selection Autoimmune Disease – Discovery World-class team TESTING THERAPEUTICS 3 Unequivocal evidence demonstrates the human gut microbiome acts systemically and is a critical component of disease Gastrointestinal conditions Nervous System Inflammatory conditions BCAAs, TMA, Hexa-lPS Infectious disease Hexa-lPS SCFAs Metabolic disorders SCFAs Gut microbiota produce metabolites BCAAs, TMA, Hexa-lPS SCFAs 2 PubMed search terms "gut microbiome" and "modulate" and "clinical study" and selecting for clinical trials and randomized controlled clinical trials. Only studies with positive results indicated in the abstracts were selected. >150 Clinical studies demonstrating that microbiome modulation can influence disease outcomes and symptoms2 4 5 Our Diagnostics Vision To combat disease through microbiome health Since 2023, Microba has executed the next step of its journey into a medical diagnostic company at the forefront of the medical application of microbiome testing. 6 Our Diagnostics Focus Patients suffering from Gastrointestinal Disease Mental Cardiovascular Gastrointestinal → Oncology Longevity Fertility Lower Gastrointestinal Disease 7 a leading cause of healthcare spend $269B3,4 37,310,000 $209B1 $219B2 Oncology Heart Disease Patients presenting annually in the US with lower GI abdominal symptoms* 21,500,000 Pain, bloating, other 15,370,000 Diarrhoea 440,000 IBD Gastrointestinal Gastrointestinal Disease Disease Annual US Healthcare Spend 1National Cancer Institute website: https://progressreport.cancer.gov/after/economic_burden; 2CDC website: https://www.cdc.gov/policy/polaris/healthtopics/heartdisease/index.html 3Nyrop et al. 2007. Alimentary Pharmacology & Therapeutics. DOI: 10.1111/j.1365-2036.2007.03370.x. 4Park et al 2019. Inflammatory Bowel Diseases. DOI:10.1093/ibd/izz104. *Assessment of Medicare claims analysis by Veranex including estimated Private and Medicaid numbers extrapolated from the Medicare claims analysis. Combined with IBS diagnosed individual data from Almario et al 2023. Gastroenterology. DOI:10.1053/j.gastro.2023.08.010 and IBD individual data from Lewis et al 2023. Gastroenterology. DOI:10.1053/j.gastro.2023.07.003 and Weisman et al 2023. Prev. Med. Rep. DOI: 10.1016/j.pmedr.2023.102173. Half of patients are not getting a resolution 8 from current standard of care 47% → Unresolved 53% Gordon, J., Miller, G., & Valenti, L. (2015). The management of unresolved gastrointestinal symptoms in Australian general practice. Australian Family Physician, 44(9), 621-623.. Resolved A multi-billion dollar market opportunity 9 Diarrhoea Immuno-compromised 0.7M* patients 35M+ US patients* Diarrhoea Immunocompetent 14.7M* patients Non-specific Lower GI symptoms & IBS 35.2M* patients >$15B US Total Addressable Market** Symptoms in IBD 0.4M* patients Ongoing market analysis with * Assessment of Medicare claims analysis. Estimated Private and Medicaid numbers extrapolated from Medicare claims analysis. ** Assumes minimum revenue per test of US $416.78 aligned to CPT code 57507. This is viewed to be the minimum with the top pricing predicate at US $2126.20 *** Addressing the GI symptom challenge 10 Microba’s comprehensive diagnostic products First line Diagnosing pathogenic causes of GI symptoms Gastrointestinal pathogen test Developed with Launched March 2024  Stool DNA test.  175 targets.  Expertly curated clinical recommendations for targeted treatment. Second line Identifying functional causes and treatment options for non-pathogenic GI symptoms Gastrointestinal disorder test Launched February 2023  Stool DNA + targeted biomarker test.  7 functional GI markers. >28k microbiome markers.  Expertly curated clinical recommendations for personalised treatment. Getting answers for patients in need 11 Closing the gap on GI symptom diagnosis and treatment Out of 100 patients presenting with lower GI symptoms 24% more diagnoses with ** 19% diagnosed with * Standard of Care (PCR +MCS+OCP) * Large pathology company data from 70,000 tests with 19% positive pathogen detection rate ** Study of first 4 months of MetaPanel test results in clinical practice in Australia Strong diagnostic performance 12 Highly specific test that enables confident diagnosis Diagnostic Performance vs standard of care Measure 175 Coverage MetaPanel Number of pathogen or gene targets on the test vs <25 Standard of care* Sensitivity 0.94 +/- 0.07 Specificity 0.99 +/- 0.01 Positive Predictive Power (PPV) 0.99 +/- 0.01 Negative Predictive Power (NPV) 0.99 +/- 0.01 Ability of a test to identify the presence of a target correctly; (= TP / (TP + FN)) Ability of a test to identify the absence of a target correctly; (= TN / (TN + FP)) Probability that an individual with a positive test result has the target (= TP / (TP + FP)) Probability that an individual with a negative test result does not have the target (= TN / (TN + FN)) Data from 517 blinded samples. Confidence measures represent median values with 95% confidence interval across pathogen species compared to one or more validated assays. *Including multiplex PCR & MCS testing Transforming standard of care 13 A paradigm shift “After the first 4 months using the MetaPanel test, 24% of patients have been diagnosed with a pathogen that would have been undiagnosed or experienced delayed time to diagnosis and resolution. This is a breakthrough in infectious disease management” Dr Michael Wehrhahn BSc (Med) MBBS (Hons) MPH (Hons) FRACP FRCPA Clinical Microbiologist, Infectious Disease Physician & Director of Molecular Biology Advancing GI pathogen diagnosis in Australia • Sales building across all states through the Sonic network • 7 clinician launch events held spanning all major states and territories • Multiple clinical utility studies initiated • Initial publications in process • Active KOL development 14 Changing lives every day “Before completing the MetaXplore test with my practitioner, my health was in constant distress. I looked and felt bloated all the time, to the point of appearing six months pregnant. My severe constipation led to bowel movements only every 5-6 days with trapped gas causing extreme pain. After completing the MetaXplore test and implementing my treatment plan, I have experienced remarkable improvements. My bowel movements are now regular, averaging every 2-3 days. The trapped gas and extreme pain are gone, significantly improving my daily life. With adherence to the treatment plan, I no longer suffer from bloating, pain, reflux, or indigestion” 15 MetaXplore patient Changing lives every day “I have struggled with gastrointestinal symptoms for over half my life. I have tried resolving with many specialists, restrictive eating plans and natural therapies. My MetaXplore test this year identified clear problems and a personalised treatment plan. I am grateful that through following the treatment plan I have achieved complete resolution to my symptoms and can enjoy eating unrestricted for the first time in 35 years.” 16 MetaXplore patient Growing sales in Australia post launch >5,800 17 2,935 Tests sold since March 2023 60% 1,841 Growth HoH 984 H2 FY23 H1 FY24 MetaXplore test sales volume H2 FY24 Growing clinical adoption in Australia post launch 723 >700 Clinicians have ordered at 30 June 2024 65% 436 Growth HoH 181 H2 FY23 H1 FY24 MetaXplore ordering clinicians H2 FY24 18 Serving patients today and driving to establish a new reimbursed standard of care Out of pocket pay access Driving access today where standard of care has failed. Full out of pocket pay. Regulatory Evidence Clinical performance validation. Case studies. Registry driving RWE. RCTs vs standard of care demonstrating clinical utility. Reimbursement & coverage 19 Guidelines Appendix 20 Patient pathway — Advancing the standard of care for GI symptoms Colonoscopy for formal IBD or CRC diagnosis and treatment Targeted antibiotic treatment New Microba care pathway If negative Current standard of care Is it a pathogen causing these symptoms? IBD risk test faecal calprotectin ELISA If negative If positive Broad spectrum antibiotic treatment DGBI Expect psychogenic IBS. Referred for mental health support Is this a functional GI disorder or mental health disorder? Is there risk of IBD or CRC? 10-22 pathogen PCR test IBD = Inflammatory Bowel Disease, CRC = Colorectal Cancer, IBS = Irritable Bowel Syndrome If negative Comprehensive gastrointestinal disorder test 175 targets Patient presents with GI symptoms. Functional microbiome or GI disorder diagnosis with personalised treatment plan If positive If positive Broadest pathogen test available and /or CRC risk test FIT or FOBT If negative IBS Diagnosis by exclusion + IBS If positive Colonoscopy for formal IBD or CRC diagnosis and treatment Non-specific diet and mental health support 21 Two core business segments driven by a world leading technology Testing Business Next generation gastrointestinal diagnostics 2 clinical tests. GASTROINTESTINAL PATHOGEN TEST GASTROINTESTINAL DISORDERS TEST World leading microbiome analysis technology Proprietary databank Advanced AI and biostatistics powering a diagnostics and therapeutics platform Therapeutics Business Precision microbiome therapeutics Data driven therapeutic development platform. ADVANCED AI/ML APPROACH UNDERPINNED BY WORLD LEADING TECHNOLOGY 3 therapeutic programs. 2 channels to market. PATHOLOGY PARTNER CHANNEL PRIMARY TARGET CLINICIANS Gastroenterologists General Practitioners Other Specialists DIRECT TO PRACTITIONER CHANNEL PRIMARY TARGET CLINICIANS Integrative General Practitioners Integrative Specialists Dieticians Nutritionists Naturopathic practitioners NOVEL PIPELINE OF MICROBIOME THERAPIES – POTENT, ORAL DELIVERY, SAFE & MANUFACTURABLE INFLAMMATORY BOWEL DISEASE PROGRAM IMMUNO-ONCOLOGY PROGRAM AUTOIMMUNE DISEASE PROGRAM CLINICAL INDICATION CLINICAL INDICATION Multiple cancers to enhance check-point inhibitor treatment response CLINICAL INDICATION Lupus, psoriatic arthritis & autoimmune liver disease Mild-moderate Ulcerative Colitis DEVELOPMENT STAGE Phase 1 Complete Phase 2 Readiness DEVELOPMENT STAGE Pre-clinical. Lead candidate selection DEVELOPMENT STAGE Discovery 22 Dr Luke Reid Chief Executive Officer luke.reid@microba.com CONTACT Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Chairman pasquale.rombola@microba.com Laboratory Princess Alexandra Hospital Woolloongabba QLD Australia